Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ. Dewint P, et al. Among authors: verhey e. Gut. 2014 Feb;63(2):292-9. doi: 10.1136/gutjnl-2013-304488. Epub 2013 Mar 23. Gut. 2014. PMID: 23525574 Clinical Trial.
The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL; HBV 99-01 Study Group. van Zonneveld M, et al. Among authors: verhey e. Aliment Pharmacol Ther. 2005 May 1;21(9):1163-71. doi: 10.1111/j.1365-2036.2005.02453.x. Aliment Pharmacol Ther. 2005. PMID: 15854180 Free article. Clinical Trial.
Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, Mach T, Leemans WF, de Man RA, Verhey E, Schalm SW, Janssen HL; HBV 99-01 Study Group. Flink HJ, et al. Among authors: verhey e. Am J Gastroenterol. 2006 Nov;101(11):2523-9. doi: 10.1111/j.1572-0241.2006.00812.x. Epub 2006 Oct 4. Am J Gastroenterol. 2006. PMID: 17029610 Clinical Trial.
Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders.
Bergmann JF, Vrolijk JM, van der Schaar P, Vroom B, van Hoek B, van der Sluys Veer A, de Vries RA, Verhey E, Hansen BE, Brouwer JT, Janssen HL, Schalm SW, de Knegt RJ. Bergmann JF, et al. Among authors: verhey e. Liver Int. 2007 Nov;27(9):1217-25. doi: 10.1111/j.1478-3231.2007.01540.x. Liver Int. 2007. PMID: 17919233 Clinical Trial.
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA, Verhey E, Hansen BE, Janssen HL. Buster EH, et al. Among authors: verhey e. Am J Gastroenterol. 2009 Oct;104(10):2449-57. doi: 10.1038/ajg.2009.371. Epub 2009 Jul 7. Am J Gastroenterol. 2009. PMID: 19584831 Clinical Trial.
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.
Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Janssen HL; PARC Study Group. Rijckborst V, et al. Among authors: verhey e. Am J Gastroenterol. 2010 Aug;105(8):1762-9. doi: 10.1038/ajg.2010.186. Epub 2010 May 11. Am J Gastroenterol. 2010. PMID: 20461068 Clinical Trial.
Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders.
Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE, Janssen HL; PARC Study Group. Rijckborst V, et al. Among authors: verhey e. Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1012-9. doi: 10.1097/MEG.0b013e3283557e23. Eur J Gastroenterol Hepatol. 2012. PMID: 22668876 Clinical Trial.
Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL; ARES Study Group. Brouwer WP, et al. Among authors: verhey e. Hepatology. 2015 May;61(5):1512-22. doi: 10.1002/hep.27586. Epub 2015 Feb 27. Hepatology. 2015. PMID: 25348661 Clinical Trial.
26 results